JID innovations : skin science from molecules to population health最新文献_第6页

Paraprotein-Negative IL-1–Mediated Inflammatory Dermatosis: An Update on Schnitzler-Like Syndrome in the Absence of a Gammopathy 副蛋白阴性il -1介导的炎症性皮肤病：无Gammopathy的schnitzler样综合征的最新进展

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-08-20 DOI: 10.1016/j.xjidi.2025.100405

Rizwan Ahmad , Jean Dunne , Katie Ridge , Nicole Fagan , Niall Conlon

{"title":"Paraprotein-Negative IL-1–Mediated Inflammatory Dermatosis: An Update on Schnitzler-Like Syndrome in the Absence of a Gammopathy","authors":"Rizwan Ahmad , Jean Dunne , Katie Ridge , Nicole Fagan , Niall Conlon","doi":"10.1016/j.xjidi.2025.100405","DOIUrl":"10.1016/j.xjidi.2025.100405","url":null,"abstract":"<div><div>Schnitzler syndrome (SchS) is a rare autoinflammatory condition characterized by chronic urticaria and systemic inflammation. Obligate diagnostic criteria include the presence of a monoclonal IgM or IgG band, with nearly all cases demonstrating a prompt response to IL-1 blockade. Recently, \"Schnitzler-like\" cases without a paraprotein have been reported. Although the exact nature of their relation to the original eponymous syndrome remains unclear, these cases share similar clinical features and response to IL-1 inhibition. Diagnostic delay is common in autoinflammatory syndromes, and the need to recognize potentially emerging cases is important. We present the case of a male aged 47 years with refractory urticaria, joint pain, and systemic inflammation resembling SchS but without detectable paraprotein, consistent with recently proposed paraprotein-negative IL-1–mediated inflammatory dermatosis (PANID). After failing conventional therapies, the patient achieved rapid and sustained remission with IL-1 blockade. This case underscores the importance of recognizing autoinflammatory syndromes, including PANID, in patients with refractory urticaria with associated inflammatory features. It also highlights the importance of a therapeutic trial of IL-1 inhibition.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100405"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145219073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Superior Antiproliferative and Enhanced Synergistic Effects of a ROCK Inhibitor in Multiple Models for Keloid Disease 一种ROCK抑制剂在多种瘢痕疙瘩疾病模型中具有卓越的抗增殖和增强的协同作用

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-07-30 DOI: 10.1016/j.xjidi.2025.100402

Zeinab Ghasemishahrestani , Traci A. Wilgus , Nonhlanhla P. Khumalo , Ardeshir Bayat

{"title":"Superior Antiproliferative and Enhanced Synergistic Effects of a ROCK Inhibitor in Multiple Models for Keloid Disease","authors":"Zeinab Ghasemishahrestani , Traci A. Wilgus , Nonhlanhla P. Khumalo , Ardeshir Bayat","doi":"10.1016/j.xjidi.2025.100402","DOIUrl":"10.1016/j.xjidi.2025.100402","url":null,"abstract":"<div><div>Keloid disease is a common fibroproliferative skin disorder characterized by excessive scar tissue formation and frequent recurrence. Limited therapies and study models hinder progress in addressing this unmet clinical need. AMA0825, a ROCK (Rho-associated protein kinase) inhibitor, has shown promising antifibrotic and antiproliferative effects in other fibrotic conditions. This study investigated the therapeutic potential of AMA0825 using in vitro, ex vivo, and a 3-dimensional spheroid model of keloid disease, which partially reflects features of the keloid microenvironment. AMA0825 demonstrated potent antiproliferative activity against keloid fibroblasts, with a half-maximal growth inhibitory concentration of 28.19 ± 1.6 nM, significantly outperforming dexamethasone (half-maximal growth inhibitory concentration = 35.35 ± 2.6 μM) and triamcinolone (half-maximal growth inhibitory concentration = 37.84 ± 3 μM). This effect was confirmed by decreased Ki-67 expression and cell cycle arrest at the G1 phase. In the 3-dimensional spheroid model, AMA0825 effectively inhibited cell proliferation at nanomolar concentrations, exceeding the efficacy of dexamethasone. Although AMA0825 did not demonstrate significant antifibrotic activity at lower concentrations, it exhibited antifibrotic effects at higher concentrations. In addition, synergistic effects were observed when combined with dexamethasone. This study highlights the potential of ROCK inhibitors, particularly AMA0825, as an antiproliferative agent for keloid disease and underscores the value of 3-dimensional spheroid models for evaluating alternative therapeutic strategies.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100402"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stimulation of Skin Pigmentation with UVR Is a Risk Factor for Cholelithiasis 紫外线照射刺激皮肤色素沉着是胆石症的危险因素

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-08-25 DOI: 10.1016/j.xjidi.2025.100408

Stanislav Pavel , Patrick A. Riley

{"title":"Stimulation of Skin Pigmentation with UVR Is a Risk Factor for Cholelithiasis","authors":"Stanislav Pavel , Patrick A. Riley","doi":"10.1016/j.xjidi.2025.100408","DOIUrl":"10.1016/j.xjidi.2025.100408","url":null,"abstract":"<div><div>Long-term clinical experience suggested that skin fairness is one of the risk factors for developing cholelithiasis. However, it was unclear how to connect skin color with the development of gallstones. The discovery of reactive melanin precursors resulted in the hypothesis that some of these compounds could be excreted via bile and form the basis of gallstones. There are indications that the excretion of these compounds from melanocytes is higher in individuals with less pigmented skin who were irradiated by UV radiation. A clinical study revealed that people with fair skin who like sunbathing run a very high risk of developing cholelithiasis. We also present several studies that report a significant increase in cholelithiasis among psoriasis patients. Most gallstones remain asymptomatic. However, some patients may develop symptoms shortly after the gallstones are formed. We cite several investigations that found the highest frequency of cholecystectomies and cases of acute pancreatitis in the summer and the lowest in the winter. We propose that skin fairness should be considered a real risk factor for cholelithiasis, but only in combination with UV stimulation of cutaneous pigmentation. In this review, we discuss the laboratory and clinical work that can be connected to this hypothesis.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100408"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Racial Differences in Work Relative Value Units for Outpatient Pediatric Dermatology Visits 儿童皮肤科门诊就诊工作相对价值单位的种族差异

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-09-02 DOI: 10.1016/j.xjidi.2025.100411

Udeyvir S. Cheema , Beiyu Liu , Ethan Borre , Cynthia L. Green , Lauren A.V. Orenstein , Suephy C. Chen

{"title":"Racial Differences in Work Relative Value Units for Outpatient Pediatric Dermatology Visits","authors":"Udeyvir S. Cheema , Beiyu Liu , Ethan Borre , Cynthia L. Green , Lauren A.V. Orenstein , Suephy C. Chen","doi":"10.1016/j.xjidi.2025.100411","DOIUrl":"10.1016/j.xjidi.2025.100411","url":null,"abstract":"<div><div>Measures of clinical productivity may tilt financial incentives toward providing care to specific patient populations, reinforcing inequitable care. Race, sex, and age have been shown to influence differences in work relative value units (wRVUs) generated during adult dermatology encounters. We sought to identify the association of patient race and sex with wRVUs generated by outpatient pediatric dermatology encounters. A total of 22,434 encounters among 10,063 unique patients were included; most encounters were with female (12,639 [56.3%]) and White (13,036 [58.1%]) individuals. The mean (SD) wRVUs per encounter was 1.57 (0.76). Visits with Asian patients, Black patients, and patients of other races generated 0.21 (95% confidence interval [CI] = 0.16–0.25), 0.19 (95% CI = 0.16–0.22), and 0.14 (95% CI = 0.10–0.17) fewer wRVUs per encounter, respectively, than pediatric outpatient dermatology visits with White patients (<em>P</em> < .001 for all). There was no significant association between sex and wRVUs per encounter. Laser treatment for vascular lesions was a mediator for the observed differences in wRVUs by race (60.5% [95% CI = 45.8–75.1%] for Asian race, 62.4% [95% CI = 52.9–71.9%] for Black race, and 53.3% [95% CI = 31.7–74.9%] for other races). Variations in wRVUs by patient race may create inadvertent incentives at the health systems level to prioritize certain groups.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100411"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review 评估皮肤免疫相关不良事件的治疗效果：一项系统综述

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-09-02 DOI: 10.1016/j.xjidi.2025.100410

Christian L. Bailey-Burke , Kristin A. Tissera , Lauren Baughman , Samantha A. Polly , Meenal Kheterpal

{"title":"Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review","authors":"Christian L. Bailey-Burke , Kristin A. Tissera , Lauren Baughman , Samantha A. Polly , Meenal Kheterpal","doi":"10.1016/j.xjidi.2025.100410","DOIUrl":"10.1016/j.xjidi.2025.100410","url":null,"abstract":"<div><div>The management of dermatologic immune–related adverse events (D-irAEs) remains inconsistent owing to variability in treatment responses and a lack of standardized guidelines. Establishing evidence-based recommendations is critical to improving patient outcomes and minimizing interruptions in immune checkpoint inhibitor therapy. This review aims to systematically evaluate the level of evidence for reported D-irAE treatments and provide insights to guide clinical decision making. Of the D-irAEs identified, those that were commonly reported include maculopapular, lichenoid, psoriasiform, immunobullous (including bullous pemphigoid), granulomatous, vitiligo, and potentially life-threatening erosive mucocutaneous conditions (such as erythema multiforme, Steven–Johnson syndrome, and toxic epidermal necrosis). Treatments ranged from corticosteroids (topical, oral, intravenous) to biologics (eg, omalizumab, rituximab) and oral immunomodulators (eg, methotrexate, apremilast), with topical and oral corticosteroids, along with apremilast, receiving the strongest evidence rating (3B). Although the strongest evidence supports corticosteroids, most treatments for D-irAEs lack robust validation owing to limitations in study type (ie, randomized control trials and prospective cohort studies). This underscores the importance of multidisciplinary approaches to optimize D-irAE management and support continuity in cancer care. Future research should prioritize randomized control trials and prospective cohort studies to aid in standardizing D-irAE treatment protocols to solidify treatment consensus.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100410"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating CLA+ Memory T Cells in Skin Diseases: A Translational Perspective 循环CLA+记忆T细胞在皮肤病中的作用

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-08-05 DOI: 10.1016/j.xjidi.2025.100403

Tali Czarnowicki , Lea Tordjman , Irene García-Jiménez , Luis F. Santamaria-Babí

引用次数: 0

Immunoregulatory Microenvironment in the Elderly Skin 老年皮肤的免疫调节微环境

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-07-22 DOI: 10.1016/j.xjidi.2025.100401

Yuri Shimizu , Hanako Koguchi-Yoshioka , Toshiki Kubo , Yutaka Matsumura , Shoichi Matsuda , Atsushi Tanemura , Michiko Nomori , Naoya Otani , Mifue Taminato , Koichi Tomita , Tateki Kubo , Manabu Fujimoto , Rei Watanabe

{"title":"Immunoregulatory Microenvironment in the Elderly Skin","authors":"Yuri Shimizu , Hanako Koguchi-Yoshioka , Toshiki Kubo , Yutaka Matsumura , Shoichi Matsuda , Atsushi Tanemura , Michiko Nomori , Naoya Otani , Mifue Taminato , Koichi Tomita , Tateki Kubo , Manabu Fujimoto , Rei Watanabe","doi":"10.1016/j.xjidi.2025.100401","DOIUrl":"10.1016/j.xjidi.2025.100401","url":null,"abstract":"<div><div>Previous studies have revealed that skin T cells accumulate and maintain immune responses in the elderly. However, we questioned why these functional T cells fail to recognize and eliminate malignant cells, making elderly skin more prone to developing malignant tumors. To address this question, we examined the overall skin microenvironment in aging using the Nanostring nCounter system and 10x Xenium digital spatial RNA sequencing. The digital RNA counts of <em>CIITA</em> and <em>HLA-DMA</em>, which are involved in antigen presentation, were negatively correlated with age, whereas the counts of <em>UBE2L3</em> and <em>SOCS1</em>, molecules that play roles in immune regulation, were positively correlated with aging. The upregulation of <em>SOCS1</em> was detected in the microenvironment of the skin malignant tumors. Spatial transcriptome analysis revealed that cells with high levels of <em>SOCS1</em> were distributed in upper dermis and periadnexal area, and some <em>SOCS1</em>-positive fibroblasts were closely lined with <em>CD163</em>-positive macrophages. Our study showed that the skin microenvironment in the elderly may shift to an immunoregulatory condition. Furthermore, modulating certain molecules that may be involved in shared immunoregulatory mechanisms between healthy elderly skin and malignant tumors could serve as a potential strategy for preventing malignancies in elderly skin.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100401"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144911802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peptide Epitopes of NC16A BP180 in the Diagnostics of Bullous Pemphigoid NC16A BP180肽表位在大疱性类天疱疮诊断中的意义

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-09-12 DOI: 10.1016/j.xjidi.2025.100415

Simon D. Lytton , Christine Wagger , Damian Meyersburg , Birgit Mussnig , Roland Lang , Roberto Maglie , Florian Anzengruber , Emiliano Antiga , Russell P. Hall , Johann W. Bauer

{"title":"Peptide Epitopes of NC16A BP180 in the Diagnostics of Bullous Pemphigoid","authors":"Simon D. Lytton , Christine Wagger , Damian Meyersburg , Birgit Mussnig , Roland Lang , Roberto Maglie , Florian Anzengruber , Emiliano Antiga , Russell P. Hall , Johann W. Bauer","doi":"10.1016/j.xjidi.2025.100415","DOIUrl":"10.1016/j.xjidi.2025.100415","url":null,"abstract":"<div><div>Bullous pemphigoid is a severe autoimmune blistering skin disorder causing significant morbidity and mortality among the elderly. Improved diagnostic strategies rely on the identification of autoantigen epitopes recognized by pathogenic autoantibodies. Continuous (linear) peptide epitopes, unlike conformational epitopes in recombinant proteins, offer advantages such as chemical stability, reproducibility, and lower production costs, making them attractive for diagnostic assay development. To identify relevant linear epitopes, a microarray of overlapping peptides spanning the NC16A domain of BP180 and the C-terminus of BP230 autoantigens was screened with sera of 13 patients with bullous pemphigoid and 2 control sera. A 25-mer peptide of NC16A, termed Pep7-NC16A, was evaluated by ELISA in 2 independent patient cohorts (n = 35 and 26 bullous pemphigoid cases, n = 48 and 53 controls). Pep7-NC16A ELISA showed sensitivity of 71% and 62% and specificity of 92% and 98%, with area under the curve values of 0.92 and 0.754 (<em>P</em> < .001). Reactivity strongly correlated with commercial BP180 NC16A ELISA (r = 0.72, <em>P</em> < .0001). In this study, we demonstrate the diagnostic potential of synthetic peptide in bullous pemphigoid. The identified epitope could also serve as a potential biomarker for BP180-associated conditions or future peptide-based immunotherapies.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100415"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to ‘Factors Associated with Adoption of Immune Checkpoint Inhibitor Treatment for Advanced Melanoma: A SEER-Medicare Cohort Study’ JID Innovations, Volume 4, Issue 4, July 2024, 100289 《采用免疫检查点抑制剂治疗晚期黑色素瘤的相关因素：一项SEER-Medicare队列研究》的勘误表《JID创新》，第4卷，第4期，2024年7月，100289

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-08-18 DOI: 10.1016/j.xjidi.2025.100407

Cassandra Mohr , Kaiping Liao , Candice L. Hinkston , Mackenzie R. Wehner , Meng Li

引用次数: 0

Divergence in Estimated Risks and Actual Rates of Atherosclerotic Cardiovascular Events and their Management in a Longitudinal Cohort of Patients with Dermatomyositis with Skin Involvement 一项累及皮肤的皮肌炎患者纵向队列中动脉粥样硬化性心血管事件的估计风险和实际发生率及其管理的差异

JID innovations : skin science from molecules to population health Pub Date : 2025-11-01 Epub Date: 2025-07-07 DOI: 10.1016/j.xjidi.2025.100399

Megan Zhao , Caroline Stone , Rui Feng , Victoria P. Werth , Kevin Jon Williams

{"title":"Divergence in Estimated Risks and Actual Rates of Atherosclerotic Cardiovascular Events and their Management in a Longitudinal Cohort of Patients with Dermatomyositis with Skin Involvement","authors":"Megan Zhao , Caroline Stone , Rui Feng , Victoria P. Werth , Kevin Jon Williams","doi":"10.1016/j.xjidi.2025.100399","DOIUrl":"10.1016/j.xjidi.2025.100399","url":null,"abstract":"<div><div>Patients with dermatomyositis (DM), an autoimmune disorder affecting the skin, muscle, and lung, have been reported to be at a heightened risk of clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease. In this study, we examined current cardiovascular management in a single-center study of all 388 patients who have DM with skin involvement, either with symptomatic muscle disease (“classic DM”) or with clinically amyopathic DM. By the new guidelines, the most recent low-density lipoprotein cholesterol levels were above goal for 290 of 388 (74.7%). Surprisingly, statin use was similar between this cohort and a longitudinal lupus cohort. Almost two thirds of the cohort had hypertension (249 of 388, 64.2%), which was undertreated or untreated in 199 of 249 (79.9%). One third of the cohort were former or current smokers. Prediabetes and diabetes were generally well-managed. Three published methods for estimating atherosclerotic cardiovascular disease event risk in primary prevention showed meaningful discordance for 196 of 305 (64.3%). The documented rate of atherosclerotic cardiovascular disease events in the first 10 years after enrollment was 12.8% for classic DM and 8.4% for clinically amyopathic DM, indicating at-risk populations. We conclude that patients with DM are undermanaged for conventional therapeutic targets to reduce atherosclerotic cardiovascular disease event risk, particularly hypercholesteremia and hypertension.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 6","pages":"Article 100399"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0